Heart Failure, Systolic
Conditions
Keywords
Metformin, Heart Failure, Organic cation transporter, Pharmacogenetics, Pharmacokinetics, Positron Emission Tomography
Brief summary
The purpose of the study is to evaluate if metformin is taken up into the failing myocardium. Recent experimental and epidemiological studies have shown beneficial effects of metformin on heart failure. It is unknown whether this effect is direct or indirect. The aim of the study is to investigate if metformin is taken up in heart failure using a novel 11C-metformin tracer and positron emission tomography (PET).
Interventions
RADIATION11C-metformin
200 MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Positron Emission Tomography
Sponsors
Henrik Wiggers
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Masking description
Open label
Intervention model description
All 6 subjects allocated to the study will receive 11C-metformin intravenously.
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Patients with chronic heart failure, Left Ventricular Ejection Fraction \<45% * New York Heart Association (NYHA) class I, II, III * Relatively preserved renal function (eGFR \> 30 ml/min) * Ability to understand the written patient information and to give informed consent * Negative p-HCG for women of childbearing potential
Exclusion criteria
* Known allergy to metformin * Age \< 18 years * Current abuse of alcohol or drugs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Metformin uptake in the failing myocardium | 12 months | Cardiac uptake is evaluated through analysis of acquired PET-images. |
Countries
Denmark
Outcome results
None listed